Is ANKTIVA the next big longevity drug?
Dr. Robert Lufkin breaks down how this FDA-approved IL-15 superagonist (from Dr. Patrick Soon-Shiong) could combat lymphopenia, boost immune function, and target multiple hallmarks of aging — beyond its current use in bladder cancer. @bullishbruk@DrPatrick
Watch here: https://t.co/Bxlyv3nG1R